TP53 and acute myeloid leukemia: Indeed, FLT3 inhibition and nutlin-3a exhibit synergy [149, 150], and there is a phase I clinical trial open for recruitment focussed on combination treatment for AML patients with mutated FLT3 and wild-type TP53 (NCT04496999) (Table 2).